Status:
COMPLETED
Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients
Lead Sponsor:
University Magna Graecia
Conditions:
Acute Respiratory Failure
SARS CoV 2 Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Coronavirus Disease (COVID-19) is characterized by a hypercoagulable state, sometimes difficult to be managed with heparin. Bivalirudin, a member of the direct thrombin inhibitor drug class, offers po...
Eligibility Criteria
Inclusion
- ratio between arterial partial pressure to inspired fraction of oxygen (PaO2/FiO2) \< 200 mmHg
- age equal or greater of 18 years/old
- detection of coronavirus 2019 at the nasal swab;
- need for endotracheal intubation and invasive mechanical ventilation
Exclusion
- known allergies to one of the two investigated drugs
- presence of hematological diseases
- pregnancy
- recent (10 days) surgery
- presence of active bleeding
Key Trial Info
Start Date :
April 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2022
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT05334654
Start Date
April 20 2022
End Date
July 30 2022
Last Update
August 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AOU Mater Domini
Catanzaro, Italy